We have investigated the relationship between TDO activity and the maintenance of genomic integrity in glioma-derived cells—uncovering evidence that KP signaling has a broad effect on the ability of glioma-derived cells to respond to RS and DNA damage generated by BCNU, a DNA alkylating agent used in the treatment of malignant brain tumors. This evidence concerns the gene TDO2 and central nervous system cancer.